Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

With IPCALAB's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 2.568000
forwardPE 26.753963
debtToEquity 14.425000
earningsGrowth 0.365000
revenueGrowth 0.086000
grossMargins 0.663150
operatingMargins 0.172730
trailingEps 32.730000
forwardEps 47.850000

Ipca Laboratories Limited's current ratio, being 2.568, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, Ipca Laboratories Limited is well-equipped to meet its immediate financial obligations without any difficulties.
IPCALAB's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
IPCALAB's low Debt-to-Equity ratio reflects the company's conservative use of debt. This shows that it isn't over-leveraged, reducing financial risk and indicating a stable financial structure, which is a positive signal for investors concerned about excessive debt burdens.
IPCALAB's forward EPS being higher than its trailing EPS points to expected growth in profitability. This suggests that the company is projected to perform better in the current financial year, with higher earnings forecasted compared to the previous year.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

The steady upward revision of IPCALAB's price projections indicates growing confidence in the company's performance. Analysts are becoming increasingly optimistic about IPCALAB's future prospects and potential for growth.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


IPCALAB had 2 sell transactions, while the market price was at 1465.7999877929688 per share.During the review period, no sell transactions were executed.An increase in buying activity relative to selling at IPCALAB's current price might suggest a favorable sentiment among investors. This trend could be interpreted as a sign that the stock has a positive outlook in the near term.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


Analysts' recent buy bias toward IPCALAB suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see IPCALAB as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.